Related Experiment Video

Updated: Sep 24, 2025

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

13.5K

Long non-coding RNA PCDRlnc1 confers docetaxel resistance in prostate cancer by promoting autophagy

Jianjun Xie1,2, Xiumei Chen3, Weiwan Wang4

  • 1Department of Urology, The First Affiliated Hospital of Soochow University, China.

Journal of Cancer
|May 6, 2022
PubMed

Insights

A novel long noncoding RNA, PCDRlnc1, drives docetaxel resistance in prostate cancer (PCa) by promoting autophagy. Inhibiting PCDRlnc1 sensitizes PCa cells to docetaxel, offering a potential therapeutic target.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Docetaxel resistance is a major challenge in prostate cancer (PCa) treatment.
  • Long noncoding RNAs (lncRNAs) are implicated in cancer chemosensitivity, but their role in PCa docetaxel resistance is unclear.

Purpose of the Study:

  • To identify novel lncRNAs involved in docetaxel resistance in prostate cancer.
  • To investigate the functional role and mechanism of a newly identified lncRNA, PCDRlnc1, in PCa docetaxel resistance.

Main Methods:

  • RNA sequencing was employed to compare lncRNA expression profiles in docetaxel-resistant and parental PCa cells.
  • In vitro and in vivo experiments assessed the effects of PCDRlnc1 knockout and overexpression on docetaxel sensitivity and autophagy.
  • Mechanistic studies explored the interaction between PCDRlnc1, UHRF1, and Beclin-1 signaling.

Main Results:

  • A novel lncRNA, PCDRlnc1 (ENSG00000234147), was identified and found to be upregulated in docetaxel-resistant PCa cells.
  • PCDRlnc1 knockout sensitized PCa cells to docetaxel both in vitro and in vivo.
  • PCDRlnc1 inhibition suppressed docetaxel-induced autophagy, while overexpression promoted it, mediated by interaction with UHRF1 and activation of Beclin-1 signaling.

Conclusions:

  • PCDRlnc1 is a key regulator of docetaxel resistance in prostate cancer.
  • PCDRlnc1 may serve as a potential biomarker for docetaxel resistance and a therapeutic target in PCa treatment.
Keywords:
AutophagyChemoresistanceLncRNAProstate cancerUHRF1

More Related Videos

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

6.9K
Quantitative Analysis of Autophagy using Advanced 3D Fluorescence Microscopy09:59

Quantitative Analysis of Autophagy using Advanced 3D Fluorescence Microscopy

Published on: May 3, 2013

18.0K

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.0K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K